Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3040% below fair value
$19.03+0.06 (+0.32%)
Close on Nov 13, 2026Market cap $1.37BP/E 9.7Yield –
Innoviva operating margin
Operating margin is operating income as a percentage of revenue.
Innoviva's operating margin for the twelve months ending Sep 30, 2026 was 38.8%. For fiscal 2025 it was 39.8%, against 46.5% the year before. The highest annual figure on record is 95.7% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.8% | −6.7 |
| FY2024 | Dec 31, 2024 | 46.5% | +9.8 |
| FY2023 | Dec 31, 2023 | 36.7% | −59.0 |
| FY2021 | Dec 31, 2021 | 95.7% | +0.4 |
| FY2020 | Dec 31, 2020 | 95.3% | +1.0 |
| FY2019 | Dec 31, 2019 | 94.4% | +3.1 |
| FY2018 | Dec 31, 2018 | 91.3% | +6.8 |
| FY2017 | Dec 31, 2017 | 84.5% | +2.9 |
| FY2016 | Dec 31, 2016 | 81.6% | +23.1 |
| FY2015 | Dec 31, 2015 | 58.5% | +460.9 |
| FY2014 | Dec 31, 2014 | -402.3% | +233.0 |
| FY2013 | Dec 31, 2013 | -635.4% | −187.4 |
| FY2012 | Dec 31, 2012 | -448.0% | −0.3 |
| FY2011 | Dec 31, 2011 | -447.7% | −124.3 |
| FY2010 | Dec 31, 2010 | -323.3% | +10.5 |
| FY2009 | Dec 31, 2009 | -333.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 39.7% | +7.6 |
| Q2 FY2026 | Jun 30, 2026 | 42.5% | −6.1 |
| Q1 FY2026 | Mar 31, 2026 | 38.9% | −7.8 |
| Q4 FY2025 | Dec 31, 2025 | 34.0% | −13.0 |
| Q3 FY2025 | Sep 30, 2025 | 32.1% | −16.2 |
| Q2 FY2025 | Jun 30, 2025 | 48.6% | −6.1 |
| Q1 FY2025 | Mar 31, 2025 | 46.7% | +13.4 |
| Q4 FY2024 | Dec 31, 2024 | 47.0% | −29.3 |
| Q3 FY2024 | Sep 30, 2024 | 48.3% | −38.0 |
| Q2 FY2024 | Jun 30, 2024 | 54.7% | −42.3 |
| Q1 FY2024 | Mar 31, 2024 | 33.3% | −63.3 |
| Q2 FY2022 | Jun 30, 2022 | 76.3% | −19.5 |
| Q1 FY2022 | Mar 31, 2022 | 86.3% | −6.6 |
| Q4 FY2021 | Dec 31, 2021 | 97.1% | +3.4 |
| Q3 FY2021 | Sep 30, 2021 | 96.6% | +1.4 |
| Q2 FY2021 | Jun 30, 2021 | 95.8% | −0.2 |
| Q1 FY2021 | Mar 31, 2021 | 92.9% | −3.8 |
| Q4 FY2020 | Dec 31, 2020 | 93.7% | −3.2 |
| Q3 FY2020 | Sep 30, 2020 | 95.2% | +2.7 |
| Q2 FY2020 | Jun 30, 2020 | 96.0% | +2.8 |
| Q1 FY2020 | Mar 31, 2020 | 96.7% | +2.2 |
| Q4 FY2019 | Dec 31, 2019 | 96.9% | +0.2 |
| Q3 FY2019 | Sep 30, 2019 | 92.5% | −1.0 |
| Q2 FY2019 | Jun 30, 2019 | 93.2% | −0.2 |
| Q1 FY2019 | Mar 31, 2019 | 94.5% | +16.8 |
| Q4 FY2018 | Dec 31, 2018 | 96.7% | +1.2 |
| Q3 FY2018 | Sep 30, 2018 | 93.5% | +11.2 |
| Q2 FY2018 | Jun 30, 2018 | 93.4% | +11.8 |
| Q1 FY2018 | Mar 31, 2018 | 77.7% | +5.2 |
| Q4 FY2017 | Dec 31, 2017 | 95.5% | +9.2 |
| Q3 FY2017 | Sep 30, 2017 | 82.3% | – |
| Q2 FY2017 | Jun 30, 2017 | 81.7% | – |
| Q1 FY2017 | Mar 31, 2017 | 72.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 86.4% | – |
See a number that looks wrong?